- Home
- DXC vs WGS Comparison
DXC vs WGS Comparison
Compare DXC & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- WGS
- Stock Information
- Founded
- DXC 1959
- WGS 2017
- Country
- DXC United States
- WGS United States
- Employees
- DXC N/A
- WGS N/A
- Industry
- DXC EDP Services
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- DXC Technology
- WGS Technology
- Exchange
- DXC Nasdaq
- WGS Nasdaq
- Market Cap
- DXC 2.6B
- WGS 2.4B
- IPO Year
- DXC N/A
- WGS N/A
- Fundamental
- Price
- DXC $13.60
- WGS $127.84
- Analyst Decision
- DXC Hold
- WGS Strong Buy
- Analyst Count
- DXC 6
- WGS 9
- Target Price
- DXC $15.60
- WGS $112.22
- AVG Volume (30 Days)
- DXC 1.6M
- WGS 476.0K
- Earning Date
- DXC 10-30-2025
- WGS 10-28-2025
- Dividend Yield
- DXC N/A
- WGS N/A
- EPS Growth
- DXC 384.35
- WGS N/A
- EPS
- DXC 2.05
- WGS 0.05
- Revenue
- DXC $12,794,000,000.00
- WGS $362,321,000.00
- Revenue This Year
- DXC N/A
- WGS $36.01
- Revenue Next Year
- DXC N/A
- WGS $19.01
- P/E Ratio
- DXC $6.62
- WGS $2,632.97
- Revenue Growth
- DXC N/A
- WGS 48.70
- 52 Week Low
- DXC $12.24
- WGS $55.17
- 52 Week High
- DXC $24.83
- WGS $136.00
- Technical
- Relative Strength Index (RSI)
- DXC 51.57
- WGS 58.25
- Support Level
- DXC $12.63
- WGS $115.68
- Resistance Level
- DXC $13.46
- WGS $128.88
- Average True Range (ATR)
- DXC 0.38
- WGS 7.45
- MACD
- DXC 0.05
- WGS 0.62
- Stochastic Oscillator
- DXC 90.69
- WGS 78.59
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.